Abstract: The action of β-secretase (BACE1) is strongly correlated with the onset of Alzheimer’s disease (AD). Aminochalcone derivatives were examined for their ability to inhibit BACE1. Parent aminochalcones showed two digit micromolar IC50s against BACE1. Potency was enhanced 10-fold or more by introducing benzenesulfonyl derivatives to the amino group: 1 (IC50 = 48.2 μM) versus 4a (IC50 = 1.44 μM) and 2 (IC50 = 17.7 μM) versus 5a (IC50 = 0.21 μM). The activity was significantly influenced by position and number of hydroxyl groups on the chalcone B-ring: 3,4-dihydroxy 5a (IC50 = 0.21 μM) > 4-hydroxy 4a (IC50 = 1.44 μM) > 2,4-dihydroxy 6 (IC50 = 3.60 μM) > 2,5-dihydroxy 7 (IC50 = 16.87 μM) > des hydroxy 4b (IC50 = 168.7 μM). Lineweaver-Burk and Dixon plots and their secondary replots indicate that compound 5a was a mixed inhibitor with reversible and time-dependent behavior. Potent BACE1 inhibitors 4a,c,f, 5a–c showed moderate inhibition against two other enzymes implicated in AD pathogenesis, acetylcholinesterase (AChE) and butyrylcholinesterase (BChE), with IC50s ranging between 56.1 ~ 95.8 μM and 19.5 ~ 79.0 μM, respectively.
Keywords: sulfonamide chalcone; Alzheimer’s disease (AD); β-secretase; acetylcholinesterase (AChE); butyrylcholinesterase (BChE); mixed inhibition
Export to BibTeX
MDPI and ACS Style
Kang, J.E.; Cho, J.K.; Curtis-Long, M.J.; Ryu, H.W.; Kim, J.H.; Kim, H.J.; Yuk, H.J.; Kim, D.W.; Park, K.H. Inhibitory Evaluation of Sulfonamide Chalcones on β-Secretase and Acylcholinesterase. Molecules 2013, 18, 140-153.
Kang JE, Cho JK, Curtis-Long MJ, Ryu HW, Kim JH, Kim HJ, Yuk HJ, Kim DW, Park KH. Inhibitory Evaluation of Sulfonamide Chalcones on β-Secretase and Acylcholinesterase. Molecules. 2013; 18(1):140-153.
Kang, Jae E.; Cho, Jung K.; Curtis-Long, Marcus J.; Ryu, Hyung W.; Kim, Jin H.; Kim, Hye J.; Yuk, Heung J.; Kim, Dae W.; Park, Ki H. 2013. "Inhibitory Evaluation of Sulfonamide Chalcones on β-Secretase and Acylcholinesterase." Molecules 18, no. 1: 140-153.